Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc. is focused on creating advanced allogeneic gamma delta T cell therapies, with significant progress seen in their lead candidate, prulacabtagene leucel (prula-cel), which has demonstrated promising efficacy in early Phase 1 trials for lupus nephritis (LN) and systemic lupus erythematosus (SLE). The company is also set to initiate a Phase 1 study for its next-generation candidate, ADI-212, targeting metastatic castration-resistant prostate cancer by mid-2026, with the potential for valuable data to emerge later that year. By leveraging third-party manufacturers for commercial-scale production, Adicet aims to minimize manufacturing risks, positioning itself favorably for upcoming advancements and potential market expansions, thus indicating a positive outlook for its stock.

Bears say

Adicet Bio Inc faces significant challenges that contribute to a negative financial outlook, including projected losses of $11.58 per share by 2026 and increased risks related to clinical efficacy and market competition. The company is grappling with the possibility of negative clinical data and slower development timelines, which could hinder its ability to secure regulatory approvals and achieve projected commercial success. Furthermore, with the lack of FDA approval for Vδ1 gamma-delta T-cell therapies and a reduced probability of clinical success for its lead candidate ADI-001, the potential for long-term dilution and decreased market share raises concerns about its financial viability.

ACET has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACET has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.